$2.59 Billion is the total value of Redmile Group, LLC's 64 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 48.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $165,205,000 | +224.1% | 4,236,017 | +50.4% | 6.38% | +187.9% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $161,509,000 | +11.9% | 10,738,658 | +7.1% | 6.24% | -0.6% |
| XNCR | Buy | XENCOR INC | $96,066,000 | +224.4% | 3,204,343 | +137.2% | 3.71% | +188.3% |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $89,728,000 | +15.7% | 2,237,607 | +1.3% | 3.46% | +2.8% |
| AVXS | New | AVEXIS INC | $78,708,000 | – | 636,900 | +100.0% | 3.04% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $74,556,000 | -17.4% | 1,095,612 | +19.9% | 2.88% | -26.7% |
| WCG | Buy | WELLCARE HEALTH PLANS INC | $66,281,000 | +128.3% | 342,309 | +137.1% | 2.56% | +102.8% |
| ABT | Buy | ABBOTT LABS | $65,678,000 | +28.3% | 1,096,100 | +22.2% | 2.54% | +14.0% |
| FATE | Buy | FATE THERAPEUTICS INC | $64,962,000 | +94.5% | 6,655,962 | +21.8% | 2.51% | +72.8% |
| RGNX | Buy | REGENXBIO INC | $63,610,000 | +34.2% | 2,130,972 | +49.5% | 2.46% | +19.2% |
| CNC | Buy | CENTENE CORP DEL | $59,826,000 | +9.5% | 559,800 | +3.4% | 2.31% | -2.7% |
| ANAB | Buy | ANAPTYSBIO INC | $54,449,000 | +135.2% | 523,150 | +127.6% | 2.10% | +109.0% |
| SYNH | New | SYNEOS HEALTH INCcl a | $54,177,000 | – | 1,526,104 | +100.0% | 2.09% | – |
| ICUI | Buy | ICU MED INC | $48,832,000 | +61.5% | 193,472 | +38.2% | 1.89% | +43.5% |
| BLUE | Buy | BLUEBIRD BIO INC | $45,607,000 | -1.4% | 267,100 | +2.8% | 1.76% | -12.5% |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $45,119,000 | – | 404,800 | +100.0% | 1.74% | – |
| TFX | Buy | TELEFLEX INC | $45,026,000 | +4.9% | 176,586 | +2.4% | 1.74% | -6.8% |
| BOLD | Buy | AUDENTES THERAPEUTICS INC | $39,321,000 | +35.4% | 1,308,526 | +40.8% | 1.52% | +20.2% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $38,393,000 | +108.4% | 2,955,565 | +47.6% | 1.48% | +85.1% |
| GLYC | Buy | GLYCOMIMETICS INC | $37,041,000 | +14.3% | 2,282,268 | +18.2% | 1.43% | +1.5% |
| EPZM | Buy | EPIZYME INC | $35,713,000 | +47.8% | 2,011,989 | +4.5% | 1.38% | +31.2% |
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $30,748,000 | -5.1% | 2,469,687 | +6.5% | 1.19% | -15.7% |
| JNCE | Buy | JOUNCE THERAPEUTICS INC | $26,426,000 | +111.4% | 1,182,393 | +20.6% | 1.02% | +87.8% |
| New | ARRAY BIOPHARMA INCnote 2.625%12/0 | $25,196,000 | – | 19,000,000 | +100.0% | 0.97% | – | |
| New | ALDER BIOPHARMACEUTICALS INCnote 2.500% 2/0 | $23,090,000 | – | 25,000,000 | +100.0% | 0.89% | – | |
| SYRS | Buy | SYROS PHARMACEUTICALS INC | $21,446,000 | +245.9% | 1,652,240 | +159.3% | 0.83% | +206.7% |
| ARGX | Buy | ARGENX SEsponsored adr | $19,193,000 | +52.0% | 238,600 | +19.3% | 0.74% | +35.0% |
| HSKA | Buy | HESKA CORP | $18,854,000 | +19.7% | 238,446 | +21.4% | 0.73% | +6.3% |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS IN | $16,458,000 | +12.3% | 821,280 | +20.1% | 0.64% | -0.2% |
| MYL | New | MYLAN N V | $15,686,000 | – | 381,000 | +100.0% | 0.61% | – |
| ARMO | New | ARMO BIOSCIENCES INC | $11,178,000 | – | 298,800 | +100.0% | 0.43% | – |
| TDOC | Buy | TELADOC INC | $11,010,000 | +110.6% | 273,200 | +82.1% | 0.42% | +87.2% |
| BGNE | New | BEIGENE LTDsponsored adr | $6,720,000 | – | 40,000 | +100.0% | 0.26% | – |
| EXAS | New | EXACT SCIENCES CORP | $328,000 | – | 8,130 | +100.0% | 0.01% | – |
| IHF | New | ISHARES TRus hlthcr pr etf | $330,000 | – | 2,087 | +100.0% | 0.01% | – |
| FLXN | New | FLEXION THERAPEUTICS INC | $223,000 | – | 9,930 | +100.0% | 0.01% | – |
| ARAY | New | ACCURAY INC | $145,000 | – | 29,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.